Home/News Feed/SELLAS Life Sciences prices $150M public offering to fund cancer therapy development SELLAS Life Sciences Group, a biopharmaceutical company focused on cancer therapies, announced the pricing of an underwritten public offering of 11.5 million shares at $13 each, raising approximately $150 million before expenses. The offering includes a 30-day option for underwriters to purchase additional shares. Proceeds will support the development of SELLAS' lead cancer treatment candidates, including GPS and SLS009. The offering is expected to close on November 20, 2026, subject to customary conditions, with major banks managing the deal.
SELLAS Life Sciences Group shares are trading at USD 17.43 on Pluang as of Nov 19, 2026 10:11 WIB, down 8.98% in the past day. The company’s market cap stands at $3.90 billion with a high trading volume of 119,486,326 shares. This trading activity coincides with the announcement of their $150 million underwritten public offering to fund cancer therapy development.